Back to Search Results
Image Place holder

Jingsong Zhang, MD, PhD


Specialty: Medical Oncology
Program: Genitourinary Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Moffitt Cancer Center at International Plaza
Overview

Cancer Focus: Prostate Cancer , Testicular Cancer , Bladder Cancer , Kidney (Renal Cell) Cancer

Dr. Jingsong Zhang is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine.  His primary interest is in developing new treatments for prostate cancer. As a member of the Moffitt experimental therapeutics program, Dr. Zhang is researching novel agents that might inhibit the repair pathway that allows cancer  cells to survive despite DNA damaging chemotherapy treatment.  He is a principal investigator in an American Society of Clinical Oncology grant to target DNA damage repair pathways in metastatic prostate cancer. Dr. Zhang received his medical degree from Peking Union Medical College in China, followed by a Ph.D. in pathology from the University of Southern California.  He served as a post-doctoral research fellow at Children’s Hospital Los Angeles, before pursuing a residency in internal medicine at New York Downtown Hospital and fellowship in hematology/oncology at University of Michigan Comprehensive Cancer Center. Dr. Zhang has been published in numerous medical journals and is board certified in both medical oncology and internal medicine.  He is fluent in English and Chinese.  

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • University of Michigan Comprehensive Cancer Center - Hematology-Oncology

Residency:

  • New York Downtown Hospital - Internal Medicine

Medical School:

  • Peking Union Medical College - MD
Participating Trials

CLINICAL TRIAL 18986
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.
Condition: Genitourinary
Intervention: AG-014447 (Rucaparib); CO-338 (Rucaparib); PF-01367338-BW (Rucaparib); Rucaparib ()
Open

CLINICAL TRIAL 19462
An Open-Label, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors and Lymphomas
Condition: Multiple
Intervention: Bay 1895344 ()
Open

CLINICAL TRIAL 19954
IMPACT: Immunotherapy in Patients with Metastatic Cancers and CDK12 Mutations
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19867
A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)
Condition: Genitourinary
Intervention: BXCL701 (); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18788
A Phase 2 Study of Check Point Inhibitor, Durvalumab (MEDI4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); Durvalumab (); MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 19367
A Phase 1b Study of Adaptive Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
Condition: Genitourinary
Intervention: ADT (); Abiraterone acetate (); Bicalutamide (); Casodex (Bicalutamide); Zytiga (Abiraterone acetate); prednisone ()
Open

CLINICAL TRIAL 20117
A Phase 1/2 Study of Regn5678 (Anti-psmaxcd28) with Cemiplimab (Anti-pd-1) in Patients with Metastatic Castration-Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); REGN5678 ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2019 Oct. Pubmedid: 31581306.
  • West JB, Dinh MN, Brown JS, Zhang J, Anderson AR, Gatenby RA. Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy. Clin Cancer Res. 2019 Jul;25(14):4413-4421. Pubmedid: 30992299. Pmcid: PMC6665681.
  • Gatenby RA, Zhang J, Brown JS. First Strike-Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction. Cancer Res. 2019 Jul;79(13):3174-3177. Pubmedid: 31221821. Pmcid: PMC6606376.
  • Yao J, Chen Y, Nguyen DT, Thompson ZJ, Eroshkin AM, Nerlakanti N, Patel AK, Agarwal N, Teer JK, Dhillon J, Coppola D, Zhang J, Perera R, Kim Y, Mahajan K. The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers. Sci Rep. 2019 Jul;9(1):9715. Pubmedid: 31273254. Pmcid: PMC6609629.
  • Mei L, Zhang J, He K, Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol. 2019 Apr.12(1):43. Pubmedid: 31018854. Pmcid: PMC6482552.
  • Gupta S, Nordquist LT, Fleming MT, Berry WR, Zhang J, Ervin SL, Eisner JR, Baskin-Bey ES, Shore ND. Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018 Nov.24(21):5225-5232. Pubmedid: 30012563.
  • Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov;4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
  • Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018 Jul.7(9):e1476816. Pubmedid: 30228944. Pmcid: PMC6140546.
  • Nerlakanti N, Yao J, Nguyen DT, Patel AK, Eroshkin AM, Lawrence HR, Ayaz M, Kuenzi BM, Agarwal N, Chen Y, Gunawan S, Karim RM, Berndt N, Puskas J, Magliocco AM, Coppola D, Dhillon J, Zhang J, Shymalagovindarajan S, Rix U, Kim Y, Perera R, Lawrence NJ, Schonbrunn E, Mahajan K. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2018 Dec.17(12):2796-2810. Pubmedid: 30242092. Pmcid: PMC6528782.
  • Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Sep;3(9):e172411. Pubmedid: 28817753. Pmcid: PMC5824288.
  • Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun. 2017 Nov;8(1):1816. Pubmedid: 29180633. Pmcid: PMC5703947.
  • You L, Brown JS, Thuijsman F, Cunningham JJ, Gatenby RA, Zhang J, Staňková K. Spatial vs. non-spatial eco-evolutionary dynamics in a tumor growth model. J Theor Biol. 2017 Dec;435:78-97. Pubmedid: 28870617.
  • Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clin Genitourin Cancer. 2017 Aug;15(4):e583-e589. Pubmedid: 28410909.
  • Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov;34(11):1567-1573. Pubmedid: 27072536.
  • Wu M, Seto E, Zhang J. E2F1 enhances glycolysis through suppressing Sirt6 transcription in cancer cells. Oncotarget. 2015 May;6(13):11252-11263. Pubmedid: 25816777. Pmcid: PMC4484454.
  • Wu M, Dickinson SI, Wang X, Zhang J. Expression and function of SIRT6 in muscle invasive urothelial carcinoma of the bladder. Int J Clin Exp Pathol. 2014 Sep;7(10):6504-6513. Pubmedid: 25400728. Pmcid: PMC4230126.
  • Wu M, Wang X, McGregor N, Pienta K, Zhang J. Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. Mol Pharmacol. 2014 Jun;85(6):866-876. Pubmedid: 24627085. Pmcid: PMC4014666.
  • Liu JJ, Zhang J. Sequencing systemic therapies in metastatic castration-resistant prostate cancer. Cancer Control. 2013 Jul;20(3):181-187. Pubmedid: 23811702.
  • Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST. Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci. 2012;42(1):81-88. Pubmedid: 22371914.
  • Zhang J, Lee J, Urba S, Foster J, Worden F. A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers. Cancer Invest. 2010 Nov;28(9):910-916. Pubmedid: 20590443.
  • Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007 Apr;67(7):3094-3105. Pubmedid: 17409416. Pmcid: PMC3906735.
  • Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 2005 Jun;65(11):4633-4644. Pubmedid: 15930281.
  • Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res. 2004 Sep;64(17):6026-6034. Pubmedid: 15342383.
  • Tsao JL, Zhang J, Salovaara R, Li ZH, Järvinen HJ, Mecklin JP, Aaltonen LA, Shibata D. Tracing cell fates in human colorectal tumors from somatic microsatellite mutations: evidence of adenomas with stem cell architecture. Am J Pathol. 1998 Oct;153(4):1189-1200. Pubmedid: 9777950. Pmcid: PMC1853055.
  • Zhang J. Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. Asian J Androl. 16(3):401-406. Pubmedid: 24589464. Pmcid: PMC4023365.